

Stanford



Sunil Arani Reddy

Clinical Assistant Professor, Medicine - Oncology

CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr Rm CC2232

MC 6501

Stanford, CA 94305

Tel (650) 736-1234

Fax (650) 736-1373

Bio

CLINICAL FOCUS

- Cancer > Cutaneous (Dermatologic) Oncology
- lymphoma/melanoma/cutaneouslymphoma
- Medical Oncology

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology

PROFESSIONAL EDUCATION

- Residency: University of Michigan GME Training Verifications (1997) MI
- Fellowship: Stanford University School of Medicine Registrar (2000) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2003)
- Internship: University of Michigan Hospital (1995) MI
- Medical Education: UCI College of Medicine (1994) CA

Research & Scholarship

CLINICAL TRIALS

- A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma, Not Recruiting
- A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma, Not Recruiting
- A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma, Not Recruiting
- A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma, Not Recruiting
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers, Not Recruiting
- A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists, Not Recruiting

- An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides, Not Recruiting
- Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level, Not Recruiting
- Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery, Not Recruiting
- Compassionate Use Trial for Unresectable Melanoma With Ipilimumab, Not Recruiting
- Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery, Not Recruiting
- Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia, Not Recruiting
- Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001, Not Recruiting
- Forodesine in the Treatment of Cutaneous T-Cell Lymphoma, Not Recruiting
- High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma, Not Recruiting
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery, Not Recruiting
- Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery, Not Recruiting
- Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome, Not Recruiting
- Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides, Not Recruiting
- Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy, Not Recruiting
- Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma, Not Recruiting
- Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides, Not Recruiting
- Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma, Not Recruiting
- Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL), Not Recruiting
- Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma, Not Recruiting
- Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma, Not Recruiting

Publications

PUBLICATIONS

- **A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders** *CLINICAL CANCER RESEARCH*
Duvic, M., Reddy, S. A., Pinter-Brown, L., Korman, N. J., Zic, J., Kennedy, D. A., Lorenz, J., Sievers, E. L., Kim, Y. H.
2009; 15 (19): 6217-6224
- **Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome** *49th Annual Meeting of the American-Society-of-Hematology*
Woo, D. K., Jones, C. R., Vanoli-Storz, M. N., Kohler, S., Reddy, S., Advani, R., Hoppe, R. T., Kim, Y. H.
AMER MEDICAL ASSOC.2009: 667-74
- **Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., Hoppe, R. T., Kim, Y. H.
2008; 59 (6): 953-957
- **Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
McCormick, A. A., Reddy, S., Reinl, S. J., Cameron, T. I., Czerwinski, D. K., Vojdani, F., Hanley, K. M., Garger, S. J., White, E. L., Novak, J., Barrett, J., Holtz, R. B., Tuse, et al
2008; 105 (29): 10131-10136
- **Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas** *BRITISH JOURNAL OF HAEMATOLOGY*
Reddy, S. A., Levy, R.
2004; 124 (5): 626-628

- **CD30(+) cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Liu, H. L., Hoppe, R. T., Kohler, S., Harvell, J. D., Reddy, S., Kim, Y. H.
2003; 49 (6): 1049-1058
- **T cell antigen receptor vaccines for active therapy of T cell malignancies** *Conference on Basic and Clinical Relevant Biology of Cutaneous T Cell Lymphoma*
Reddy, S. A., Okada, C., Wong, C., Bahler, D., Levy, R.
NEW YORK ACAD SCIENCES.2001: 97-105
- **Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Stockerl-Goldstein, K. E., Reddy, S. A., Horning, S. J., Blume, K. G., Chao, N. J., Hu, W. W., JOHNSTON, L. J., Long, G. D., Strober, S., Wong, R. M., Feiner, R. H., Kohler, S., Negrin, et al
2000; 6 (5): 506-512